Respiratory pathogens are best countered at the mucosal surfaces where infection begins. Vaccine delivery routes that place antigen directly on respiratory mucosa produce local secretory IgA, tissue-resident memory T cells, and reduced viral shedding—immune outcomes linked to lower transmission and milder disease. Evidence from mucosal immunology emphasizes route-specific benefits and trade-offs. Jan Holmgren University of Gothenburg and Christopher Czerkinsky Karolinska Institutet explain that mucosal administration preferentially induces secretory IgA and mucosal homing of effector cells, mechanisms not reliably produced by intramuscular injection.
Intranasal and inhaled vaccines
Intranasal live attenuated vaccines and aerosolized formulations target the upper and lower respiratory mucosa directly. Intranasal live attenuated influenza vaccines have been associated with robust nasal IgA responses and decreased viral replication in the nasopharynx, translating into reduced transmission in some populations. Aerosolized delivery aims to reach bronchoalveolar surfaces and can generate local tissue-resident memory T cells that improve protection against lower respiratory infection. The World Health Organization highlights intranasal and inhaled approaches as promising strategies for inducing mucosal immunity against respiratory viruses while noting technical and safety considerations for live platforms.Oral routes, mucosal adjuvants, and delivery technologies
Oral vaccines primarily stimulate gut-associated lymphoid tissue but can contribute to a broader common mucosal immune system, seeding distal mucosal sites under certain conditions. Practical advantages include needle-free administration and easier acceptance in communities where injections are culturally sensitive. Advances in mucosal adjuvants, such as cholera toxin subunit derivatives and toll-like receptor agonists, and in particulate carriers like nanoparticles and liposomes, enhance antigen uptake at mucosal surfaces and skew responses toward secretory IgA and mucosal T cell induction. Regulatory guidance from the Centers for Disease Control and Prevention emphasizes careful evaluation of adjuvants and live components, especially for immunocompromised individuals.Direct mucosal delivery improves transmission-blocking potential and can reduce disease burden at the population level, but it raises logistical and safety questions: cold-chain stability, manufacturability, variable mucosal responsiveness across age and nutritional status, and contraindications for live vaccines. Contextual factors such as local healthcare infrastructure, cultural acceptance of nasal or oral administration, and environmental constraints on storage and aerosol dispersion will shape which methods are most effective in a given territory.